Affordable Access

Access to the full text

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry

  • Rahman, Proton1
  • Starr, Michael2
  • Haaland, Derek3
  • Bessette, Louis4
  • Teo, Michelle5
  • Rampakakis, Emmanouil6
  • Lehman, Allen J.7
  • Nantel, Francois7
  • 1 Memorial University, St. John’s, NL, Canada , St. John’s (Canada)
  • 2 McGill University, Montreal, QC, Canada , Montreal (Canada)
  • 3 3 , Barrie (Canada)
  • 4 Universite Laval, Quebec, QC, Canada , Quebec (Canada)
  • 5 5 , Penticton (Canada)
  • 6 JSS Medical Research, Montreal, QC, Canada , Montreal (Canada)
  • 7 Janssen Inc., 19 Green Belt Dr., Toronto, ON, M3C 1N9, Canada , Toronto (Canada)
Published Article
BMC Rheumatology
BioMed Central
Publication Date
Nov 15, 2020
DOI: 10.1186/s41927-020-00158-z
Springer Nature


BackgroundThe objectives of this study were to describe the profile of ankylosing spondylitis (AS) patients treated with either infliximab (IFX) or subcutaneous golimumab (GLM) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety.MethodsAS patients who were eligible for treatment with IFX or subcutaneous GLM as per their respective Canadian product monographs were enrolled into the BioTRAC registry from 2005 to 2017. The study visits occurred at baseline and every 6 months thereafter. Effectiveness was assessed by changes in clinical outcomes and acute phase reactants. Safety was evaluated by assessing the incidence of adverse events (AEs) and drug survival rates.ResultsA total of 389 IFX- and 421 GLM-treated patients were enrolled. A significant decrease in disease duration at baseline was observed in the IFX cohort, from a median of 8.0 in 2005–2008 to 1.0 years in 2009–2015 (p < 0.001). A reduction in baseline BASFI score (p = 0.011) and proportion of patients in ASDAS very high disease activity (p = 0.004) was also observed over time. Meanwhile, in the GLM cohort, most disease parameters remained similar from 2010 to 2017.Treatment with both agents significantly improved all disease parameters over time with similar efficacy between the two agents. The incidence of AEs and SAEs were 136 and 131 events/100 PYs and 10.5 and 8.45 events/100 PYs for IFX- and GLM-treated patients, respectively.ConclusionBoth IFX and GLM treatment in AS significantly reduced disease activity in most outcome measures in a similar fashion and were well tolerated in Canadian routine care.Trial registrationNCT00741793.

Report this publication


Seen <100 times